The NAD metabolome - a key determinant of cancer cell biology

被引：515

作者：

Chiarugi, Alberto ^{[2
]}

Dolle, Christian ^{[1
]}

Felici, Roberta ^{[2
]}

Ziegler, Mathias ^{[1
]}

机构：

[1] Univ Bergen, Dept Mol Biol, N-5008 Bergen, Norway

[2] Univ Florence, Dept Preclin & Clin Pharmacol, I-50139 Florence, Italy

来源：

NATURE REVIEWS CANCER | 2012年 / 12卷 / 11期

关键词：

NMN/NAMN ADENYLYLTRANSFERASE NMNAT; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; DIPHOSPHOPYRIDINE NUCLEOTIDE; POLY(ADP-RIBOSE) POLYMERASE; SIRTUIN; PHASE-I; SUBCELLULAR COMPARTMENTATION; SYNTHETIC LETHALITY; TUMOR PROMOTER; PROTEIN SIR2;

D O I：

10.1038/nrc3340

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NAD is a vital molecule in all organisms. It is a key component of both energy and signal transduction - processes that undergo crucial changes in cancer cells. NAD(+)-dependent signalling pathways are many and varied, and they regulate fundamental events such as transcription, DNA repair, cell cycle progression, apoptosis and metabolism. Many of these processes have been linked to cancer development. Given that NAD(+)-dependent signalling reactions involve the degradation of the molecule, permanent nucleotide resynthesis through different biosynthetic pathways is crucial for incessant cancer cell proliferation. This necessity supports the targeting of NAD metabolism as a new therapeutic concept for cancer treatment.

引用

页码：741 / 752

页数：12

共 135 条

[1] Players in the PARP-1 cell-death pathway: JNK1 joins the cast [J].

Alano, Conrad C. ;

Swanson, Raymond A. .

TRENDS IN BIOCHEMICAL SCIENCES, 2006, 31 (06) :309-311

[2] SIRT3 and cancer: Tumor promoter or suppressor? [J].

Alhazzazi, Turki Y. ;

Kamarajan, Pachiyappan ;

Verdin, Eric ;

Kapila, Yvonne L. .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2011, 1816 (01) :80-88

[3] Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses [J].

Anastasiou, Dimitrios ;

Poulogiannis, George ;

Asara, John M. ;

Boxer, Matthew B. ;

Jiang, Jian-kang ;

Shen, Min ;

Bellinger, Gary ;

Sasaki, Atsuo T. ;

Locasale, Jason W. ;

Auld, Douglas S. ;

Thomas, Craig J. ;

Vander Heiden, Matthew G. ;

Cantley, Lewis C. .

SCIENCE, 2011, 334 (6060) :1278-1283

[4]

[Anonymous], 1998, DIET REF INT THIAM R

[5] Altered sirtuin expression is associated with node-positive breast cancer [J].

Ashraf, N. ;

Zino, S. ;

MacIntyre, A. ;

Kingsmore, D. ;

Payne, A. P. ;

George, W. D. ;

Shiels, P. G. .

BRITISH JOURNAL OF CANCER, 2006, 95 (08) :1056-1061

[6] PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation [J].

Bai, Peter ;

Canto, Caries ;

Oudart, Hugues ;

Brunyanszki, Attila ;

Cen, Yana ;

Thomas, Charles ;

Yamamoto, Hiroyasu ;

Huber, Aline ;

Kiss, Borbala ;

Houtkooper, Riekelt H. ;

Schoonjans, Kristina ;

Schreiber, Valerie ;

Sauve, Anthony A. ;

Menissier-de Murcia, Josiane ;

Auwerx, Johan .

CELL METABOLISM, 2011, 13 (04) :461-468

[7]

BALOBANGA JM, 1984, CANCER RES, V44, P5004

[8] SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation [J].

Barber, Matthew F. ;

Michishita-Kioi, Eriko ;

Xi, Yuanxin ;

Tasselli, Luisa ;

Kioi, Mitomu ;

Moqtaderi, Zarmik ;

Tennen, Ruth I. ;

Paredes, Silvana ;

Young, Nicolas L. ;

Chen, Kaifu ;

Struhl, Kevin ;

Garcia, Benjamin A. ;

Gozani, Or ;

Li, Wei ;

Chua, Katrin F. .

NATURE, 2012, 487 (7405) :114-+

[9] Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777 [J].

Beauparlant, Pierre ;

Bedard, Dominique ;

Bernier, Cynthia ;

Chan, Helen ;

Gilbert, Karine ;

Goulet, Daniel ;

Gratton, Michel-Olivier ;

Lavoie, Manon ;

Roulston, Anne ;

Turcotte, Emilie ;

Watson, Mark .

ANTI-CANCER DRUGS, 2009, 20 (05) :346-354

[10] NAD+ metabolism in health and disease [J].

Belenky, Peter ;

Bogan, Katrina L. ;

Brenner, Charles .

TRENDS IN BIOCHEMICAL SCIENCES, 2007, 32 (01) :12-19

← 1 2 3 4 5 6 7 8 9 10 →